Defence Therapeutics: Making a Global Impact

Defence Therapeutics is a Canadian Biotech company developing next generation bio-pharmaceutical innovations for various immuno-oncology (IO) and infectious diseases (ID) indications.

Defence Therapeutics

Stocks to Invest in: Healthcare

Defence Therapeutics is a Canadian Biotech company developing next generation biopharmaceutical innovations for various immuno-oncology (IO) and infectious diseases (ID) indications.

The company is located in Quebec, and their leadership team brings extensive eperience in the capital markets, finance, biochemistry, pharmacology, biotech, immunology.

Their platform is known as ACCUM, which is suitable to enhance the delivery of proteins, RNA and DNA.

Accum is overcoming problematic cell recycling and rejection patterns, ACCUM™ is the first solution to enable ADCs to control intracellular delivery of chemotherapeutic drugs, resulting in superior pre-clinical anti-tumor activity.

For more information on Defence Therapeutics Inc. (CSE: DTC, OTC: DTCFF) please click the request investor info button.


You might also like

Kirkland Lake Discoveries Targets Multi-Mineral Potential in Ontario
Metals & Mining
March 13, 2026

Kirkland Lake Discoveries Targets Multi-Mineral Potential in Ontario

Exploration in mature camps often centers on new interpretations of old systems. Kirkland Lake Discoveries is testing that thesis.

This is some text inside of a div block.
CEO Clips - Kirkland Lake Discoveries Advances 25,000m Drill Program in Historic Ontario Camp
Metals & Mining
March 13, 2026

CEO Clips - Kirkland Lake Discoveries Advances 25,000m Drill Program in Historic Ontario Camp

Kirkland Lake has been a producing mining camp for more than 100 years.

This is some text inside of a div block.
Picard Medical Advancing Total Artificial Heart Technology
Health & Wellness
March 11, 2026

Picard Medical Advancing Total Artificial Heart Technology

The potential need for technologies like total artificial hearts remains significant as the number of patients with advanced heart failure continues to outpace the availability of donor organs.

This is some text inside of a div block.
Subscribe and receive the investor Info